Table 3 Haplotype distribution in BOSpos patients (n = 20), BOSneg patients (n = 87) and healthy controls (n = 422)a
Haplotypes | Homozygotes, n(%) | Heterozygotes, n(%) | Carriers, n(%) |
|---|---|---|---|
CTCC | Â | Â | Â |
   BOSpos | 1 (5) | 9 (45) | 10 (50) |
   BOSneg | 12 (14) | 49 (56) | 61 (70) |
   Controls | 61 (14) | 218 (52) | 279 (66) |
CTTC | Â | Â | Â |
   BOSpos | 1 (5) | 4 (20) | 5 (25) |
   BOSneg | 0 (0) | 12 (14) | 12 (14) |
   Controls | 2 (0.5) | 52 (12) | 54 (13) |
CCTTb | Â | Â | Â |
   BOSpos | 2 (10) | 3 (15) | 5 (25) |
   BOSneg | 0 (0) | 15 (17) | 15 (17) |
   Controls | 4 (1) | 75 (18) | 79 (19) |
ATCC | Â | Â | Â |
   BOSpos | 0 (0) | 4 (20) | 4 (20) |
   BOSneg | 0 (0) | 20 (23) | 20 (23) |
   Controls | 10 (2) | 60 (14) | 70 (16) |
ATTC | Â | Â | Â |
   BOSpos | 0 (0) | 4 (20) | 4 (20) |
   BOSneg | 0 (0) | 17 (20) | 17 (20) |
   Controls | 4 (1) | 76 (18) | 80 (19) |
ACTT | Â | Â | Â |
   BOSpos | 0 (0) | 1 (5) | 1 (5) |
   BOSneg | 0 (0) | 10 (11) | 10 (11) |
   Controls | 1 (0.5) | 70 (17) | 71 (17) |